PD17-06 THE IMPACT OF ADDING A MAPPING BIOPSY PRIOR TO PRIMARY CRYOTHERAPY FOR THE TREATMENT OF PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy I (PD17)1 Apr 2020PD17-06 THE IMPACT OF ADDING A MAPPING BIOPSY PRIOR TO PRIMARY CRYOTHERAPY FOR THE TREATMENT OF PROSTATE CANCER Al Barqawi, Rodrigo Rodrigues Pessoa*, Tracey MacDermott, Mohammed Al-Musawi, and Colin O'Donnell Al BarqawiAl Barqawi More articles by this author , Rodrigo Rodrigues Pessoa*Rodrigo Rodrigues Pessoa* More articles by this author , Tracey MacDermottTracey MacDermott More articles by this author , Mohammed Al-MusawiMohammed Al-Musawi More articles by this author , and Colin O'DonnellColin O'Donnell More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000860.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: There is no consensus on the ideal initial workup for men undergoing prostate cryotherapy (PCT). We aimed to study the implications of adding a 3D mapping biopsy (3DMB) prior to CT for the treatment of prostate cancer (PCa) on the following outcomes: recurrence and biochemical failure (BCF), quality of life outcomes, and complication rates METHODS: A retrospective analysis of patients treated with either targeted focal therapy (TFT), subtotal or whole-gland CT for low and intermediate-risk PCa was performed. The cohort was stratified by patients who had only had a TRUS biopsy and those who had undergone one additional 3DMB before definitive treatment. Pre and post-procedural Prostate Symptom Score (IPSS) and Sexual Health Inventory for Men (SHIM) surveys were collected. Complications reported were urinary retention, urinary tract infection, and urethral stricture. BCF was defined using the Phoenix criteria. Patients with BCF were re-biopsied. Differences in pre/post changes in IPSS and SHIM scores were examined with Mann-Whitney U tests, binary measures with chi-square tests, and pre/post changes in PSA with t-tests. A Kaplan-Meier time to BCF analysis is presented RESULTS: A total of 534 patients underwent PCT following either TRUS (n= 331) or TRUS and a confirmatory 3DMB (n=203) between March 2007 and June 2016. Patient characteristics are depicted in table 1. No differences were observed in either IPSS (p=0.60) or SHIM score (p=0.21) drops between groups after surgery. PSA drop was higher in the TRUS biopsy group compared to the 3DMB (p <0.05). Recurrence rate was lower in the 3DMB group (p=0.01). BCF rates were also lower in the 3DMB group (p< 0.05), figure 1. There was a higher rate of complications detected in the TRUS group (p=0.02) CONCLUSIONS: Recurrence and BCF rates were lower among patients who underwent a confirmatory 3DMB before PCT, most likely due to better risk stratification in these patients. The addition of a 3DMB did not seem to adversely impact neither rate of complications nor functional outcomes Source of Funding: none © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e371-e371 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Al Barqawi More articles by this author Rodrigo Rodrigues Pessoa* More articles by this author Tracey MacDermott More articles by this author Mohammed Al-Musawi More articles by this author Colin O'Donnell More articles by this author Expand All Advertisement PDF downloadLoading ...